Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Marie‐Camille Chaumais"'
Autor:
Clément Jambon-Barbara, Alex Hlavaty, Claire Bernardeau, Hélène Bouvaist, Marie-Camille Chaumais, Marc Humbert, David Montani, Jean-Luc Cracowski, Charles Khouri
Publikováno v:
ERJ Open Research, Vol 10, Iss 4 (2024)
Introduction Pulmonary arterial hypertension (PAH) is a rare and severe disease for which most of the evidence about prognostic factors, evolution and treatment efficacy comes from cohorts, registries and clinical trials. We therefore aimed to develo
Externí odkaz:
https://doaj.org/article/4877d888c5614c3880dc4031d422a2e0
Autor:
Antoine Le Bozec, Virginie Korb-Savoldelli, Claire Boiteau, Agnès Dechartres, Salma Al Kahf, Olivier Sitbon, David Montani, Xavier Jaïs, Christophe Guignabert, Marc Humbert, Laurent Savale, Marie-Camille Chaumais
Publikováno v:
European Respiratory Review, Vol 33, Iss 173 (2024)
Introduction Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are life-threatening conditions that can progress to death without treatment. Although strong medication adherence (MA) is known to enhance o
Externí odkaz:
https://doaj.org/article/c92de553069e4a918b2d68d6caaae9d5
Autor:
Pierre Mouillot, Nicolas Favrolt, Charles Khouri, Aurélie Grandvuillemin, Marie-Camille Chaumais, Déborah Schenesse, Andrei Seferian, Xavier Jais, Laurent Savale, Guillaume Beltramo, Olivier Sitbon, Jean-Luc Cracowski, Marc Humbert, Marjolaine Georges, Philippe Bonniaud, David Montani
Publikováno v:
ERJ Open Research, Vol 10, Iss 3 (2024)
Background Despite its known cardiac and lung toxicities, the chemotherapy drug gemcitabine has only rarely been associated with pulmonary hypertension (PH), and the underlying mechanism remains unclear. The objective of the present study was to asse
Externí odkaz:
https://doaj.org/article/95a0957952bc4c61b9da2d6e13b4032d
Autor:
David Montani, Fabrice Antigny, Etienne-Marie Jutant, Marie-Camille Chaumais, Hélène Le Ribeuz, Julien Grynblat, Charles Khouri, Marc Humbert
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
The ATP-sensitive potassium channels and their regulatory subunits, sulfonylurea receptor 1 (SUR1/Kir6.2) and SUR2/Kir6.1, contribute to the pathophysiology of pulmonary hypertension (PH). Loss-of-function pathogenic variants in the ABCC8 gene, which
Externí odkaz:
https://doaj.org/article/0b1daad67e1742e7ae47fb4de467b6e4
Autor:
Jean Hagenburg, Laurent Savale, Benoit Lechartier, Maria‐Rosa Ghigna, Marie‐Camille Chaumais, Xavier Jaïs, Olivier Sitbon, Marc Humbert, David Montani
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-12 (2021)
Busulfan is widely used to treat malignant diseases, particularly for therapeutic intensification prior to an autologous stem cell graft. Numerous side effects consecutive to busulfan are described, but few descriptions of pulmonary hypertension exis
Externí odkaz:
https://doaj.org/article/38f4fa15165248588487b71868c3286c
Autor:
Céline Cheron, Susan Ainslie McBride, Fabrice Antigny, Barbara Girerd, Margot Chouchana, Marie-Camille Chaumais, Xavier Jaïs, Laurent Bertoletti, Olivier Sitbon, Jason Weatherald, Marc Humbert, David Montani
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
Pulmonary arterial hypertension (PAH) is a rare disease characterised by pulmonary vascular remodelling and elevated pulmonary pressure, which eventually leads to right heart failure and death. Registries worldwide have noted a female predominance of
Externí odkaz:
https://doaj.org/article/d119be155f6c4aca910ba95bb2c4a876
Autor:
David Montani, Laurent Bertoletti, Marie-Camille Chaumais, Swanny Perrin, Dominique Fabre, Ari Chaouat, Xavier Jaïs, Gérald Simonneau, Marc Humbert
Publikováno v:
European Respiratory Review, Vol 23, Iss 132, Pp 260-263 (2014)
Externí odkaz:
https://doaj.org/article/4563adbe98a64cee9228f0ff9ccfedb0
Autor:
Amparo Buenestado, Marie-Camille Chaumais, Stanislas Grassin-Delyle, Paul-André Risse, Emmanuel Naline, Elisabeth Longchampt, Hermann Tenor, Philippe Devillier
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74640 (2013)
BackgroundRoflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of
Externí odkaz:
https://doaj.org/article/de9a65066ccf468bb4e118f196475e88
Autor:
Benjamin Le Vely, Carole Phan, Nihel Berrebeh, Raphaël Thuillet, Mina Ottaviani, Mustapha Kamel Chelgham, Marie-Camille Chaumais, Larbi Amazit, Marc Humbert, Alice Huertas, Christophe Guignabert, Ly Tu
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology
American Journal of Respiratory Cell and Molecular Biology, American Thoracic Society, 2022, Online ahead of print. ⟨10.1165/rcmb.2021-0332oc⟩
American Journal of Respiratory Cell and Molecular Biology, American Thoracic Society, 2022, Online ahead of print. ⟨10.1165/rcmb.2021-0332oc⟩
International audience; Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by the dysfunction of pulmonary endothelial cells (ECs) and obstructive vascular remodeling. The non-receptor tyrosine kinase c-Abelson (cA
Autor:
Marie-Caroline Certain, David Montani, Arnaud Bourdin, Vincent Cottin, Marjolaine Georges, Florence Parent, Marie-Camille Chaumais, Sébastien Renard, Violaine Noel, François Picard, Andrei Seferian, Barbara Girerd, Laurent Savale, Nicolas Favrolt, Olivier Sitbon, Xavier Jaïs, Marc Humbert, Clément Boissin, Philippe Bonniaud, Julie Traclet, Frédéric Perros, Maria-Rosa Ghigna
Publikováno v:
Chest
Chest, American College of Chest Physicians, 2021, 159 (3), pp.1197-1207. ⟨10.1016/j.chest.2020.09.238⟩
Chest, American College of Chest Physicians, 2021, 159 (3), pp.1197-1207. ⟨10.1016/j.chest.2020.09.238⟩
International audience; BACKGROUND: Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) predominantly characterized by pulmonary vein and capillary involvement. An association between chemotherapy, in particular